FG-4592
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for FG-4592, covering 2011-06-20 to 2023-05-03. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS) [Phase 2, Phase 3]